Podcasts

Episode 36 | Antibody Drug Conjugates (ADCs): An Emerging Treatment Platform in Lung Cancer

Thoracic Oncology Group of Australasia podcast, hosted by: A/Prof Melissa Moore, A/Prof Tom John and A/Prof Adnan Nagrial

Antibody Drug Conjugates (ADCs) – An Emerging Treatment Platform in Lung Cancer

In this TOGA Podcast the speakers discuss Antibody Drug Conjugates (ADCs) – An Emerging Treatment Platform in Lung Cancer. The discussion explores the different molecules and mechanisms of drugs currently available, trial results and the subsequent place of ADCs in the Lung Cancer. Furthermore, our guests expand upon the management of patients receiving these drugs.

A/Prof Melissa Moore, Medical Oncologist at St Vincent’s Hospital Melbourne, is joined in this conversation by fellow medical oncologists A/Prof Tom John from Peter MacCallum Cancer Centre in Melbourne and A/Prof Adnan Nagrial from Westmead Hospital in Sydney.

Play Episode 36 | Antibody Drug Conjugates (ADCs): An Emerging Treatment Platform in Lung Cancer

More Podcasts

50 – The Role of Liquid Biopsy in Modern Oncology

Podcasts
March 21, 2025

In this episode, Dr. Malinda Itchins, Dr. Annie Wong, and A/Prof Steven Kao discuss the concept of liquid biopsy, its advantages and limitations, and its

49 – Exploring EGFR Exon 20 Insertion Mutations

Podcasts
March 7, 2025

In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore, along with thoracic oncologists Dr. Malinda Itchins and A/Prof Surein Arulananda, delve into

48 – A Conversation with Prof. Michael Boyer

Podcasts
February 6, 2025

In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore interviews Prof Michael Boyer, AM about his extensive career in medical oncology and

47 – Introducing Conversations in Lung Cancer Research

Podcasts
February 6, 2025

In this introductory episode, A/Prof Mel Moore, announces the evolution of TOGA podcasts to 'Conversations in Lung Cancer Research.'

46 – Navigating Resistance in ALK-Positive NSCLC Patients on TKI Therapy

Podcasts
December 13, 2024

Dr Rebecca Tay is joined by Professor Ben Solomon and A/Prof Michael Ng to discuss clinical and genetic factors affecting treatment choice for ALK-Positive NSCLC

45 – The Case For IO in Early-Stage NSCLC in a Once in a Lifetime World

Podcasts
December 2, 2024

Dr Deme Karikios is joined by Dr Lauren Brown and Dr Stephen Barnett to discuss IO in early-stage NSCLC in the Australian context.

Join our community – stay up to date with the latest research, TOGA news and events

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Contact

PO Box 1103
Thornbury VIC 3071
Ph: +61 3 9087 3550
ABN: 47 641 984 198

TOGA

Quicklinks

Thoracic Oncology Group of Australasia is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations $2 and over are tax deductible.